PMID- 33257051 OWN - NLM STAT- MEDLINE DCOM- 20210507 LR - 20240330 IS - 1873-5487 (Electronic) IS - 0188-4409 (Print) IS - 0188-4409 (Linking) VI - 52 IP - 3 DP - 2021 Apr TI - Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. PG - 261-269 LID - S0188-4409(20)31189-9 [pii] LID - 10.1016/j.arcmed.2020.11.006 [doi] AB - Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition. CI - Copyright (c) 2020 IMSS. Published by Elsevier Inc. All rights reserved. FAU - Baburaj, Gayathri AU - Baburaj G AD - Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Thomas, Levin AU - Thomas L AD - Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. FAU - Rao, Mahadev AU - Rao M AD - Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Electronic address: mahadev.rao@manipal.edu. LA - eng PT - Journal Article PT - Review DEP - 20201117 PL - United States TA - Arch Med Res JT - Archives of medical research JID - 9312706 RN - 0 (Antineoplastic Agents) RN - 0 (Antiviral Agents) SB - IM MH - Antineoplastic Agents/*pharmacology MH - Antiviral Agents/*pharmacology MH - COVID-19/epidemiology MH - Drug Interactions MH - *Drug Repositioning MH - Humans MH - Lung Neoplasms/*drug therapy MH - Pandemics MH - SARS-CoV-2/*pathogenicity MH - *COVID-19 Drug Treatment PMC - PMC7670900 OTO - NOTNLM OT - COVID-19 OT - Chemotherapy OT - Drug-drug interactions OT - Lung cancer OT - QT prolongation OT - Tyrosine kinase inhibitors EDAT- 2020/12/02 06:00 MHDA- 2021/05/08 06:00 PMCR- 2020/11/17 CRDT- 2020/12/01 05:43 PHST- 2020/06/27 00:00 [received] PHST- 2020/11/03 00:00 [revised] PHST- 2020/11/12 00:00 [accepted] PHST- 2020/12/02 06:00 [pubmed] PHST- 2021/05/08 06:00 [medline] PHST- 2020/12/01 05:43 [entrez] PHST- 2020/11/17 00:00 [pmc-release] AID - S0188-4409(20)31189-9 [pii] AID - 10.1016/j.arcmed.2020.11.006 [doi] PST - ppublish SO - Arch Med Res. 2021 Apr;52(3):261-269. doi: 10.1016/j.arcmed.2020.11.006. Epub 2020 Nov 17.